title: Breaking through the central tolerance ceiling to unleash anticancer immune responses.
abstract: Central thymic tolerance mechanisms create a formidable barrier against the generation of self-reactive T cells. While preventing autoimmunity, this barrier also limits an effective antitumor immunological response. We recently reported that anti-RANKL blocking antibody breaches this central tolerance barrier, thus increasing the repertoire of melanoma reactive T cells. Thus, central tolerance blockade may be an effective therapeutic strategy to enhance anticancer immunity.
authors.affiliation: Department of Pediatrics/Microbiology and Immunology; University of North Carolina at Chapel Hill ; Chapel Hill, NC USA.
authors.forename: Maureen A
authors.initials: MA
authors.lastname: Su
authors.affiliation: Diabetes Center; University of California ; San Francisco, CA USA.
authors.forename: Mark S
authors.initials: MS
authors.lastname: Anderson
keywords: T cell; antibody therapy; immune tolerance; melanoma; thymus